New oral cancer drug targets immune system in advanced tumors

NCT ID NCT06425926

Summary

This early-stage study is testing a new oral medication called GIM-531 for people with advanced solid tumors that have stopped responding to standard treatments. The research will evaluate the drug's safety and effectiveness when taken alone and when combined with an existing immunotherapy. The study aims to find the right dose and see if this approach can help control cancer growth in patients who have limited treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Comprehensive Blood and Cancer Center

    RECRUITING

    Bakersfield, California, 93309, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • HonorHealth Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana

    RECRUITING

    Billings, Montana, 59102, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Providence Medical Foundation

    RECRUITING

    Fullerton, California, 92835, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tennessee Oncology, PLLC

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact

  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

    RECRUITING

    Los Angeles, California, 90025, United States

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UCSF Helen Diller Family Comprehensive Cancer Center

    RECRUITING

    San Francisco, California, 94143, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Cincinnati Cancer Center

    RECRUITING

    Cincinnati, Ohio, 45267, United States

    Contact

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23219, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • Weill Cornell Medicine - New York Presbyterian Hospital

    RECRUITING

    New York, New York, 10065, United States

    Contact

Conditions

Explore the condition pages connected to this study.